ACME LaboratoriesDHA:ACMELAB +0.24%82 Days Payable is 7.59 as of Mar. 2026, which is 29% below its 10-year median of 10.71. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT125.14 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 919 Drug Manufacturers companies, ACME Laboratories ranks worse than 98.91% on this metric.
The historical rank and industry rank for ACME Laboratories's Days Payable or its related term are showing as below:
DHA:ACMELAB'
s Days Payable Range Over the Past 10 Years
Min: 8.57 Med: 10.71 Max: 18.37
Current: 10.23
During the past 9 years, ACME Laboratories's highest Days Payable was 18.37. The lowest was 8.57. And the median was 10.71.
DHA:ACMELAB's Days Payable is ranked worse than 98.91% of 919
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs DHA:ACMELAB: 10.23
ACME Laboratories's Days Payable
declined
from Dec. 2024 (10.25) to Mar. 2026 (7.59).
It may suggest that ACME Laboratoriesaccelerated paying its suppliers.
ACME Laboratories Days Payable Related Terms
ACME Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ACME Laboratories's Days Payable for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a Days Payable of 7.59 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ACME Laboratories and its competitors. This is 29% below median its historical median of 10.71. Over the past decade, ACME Laboratories' Days Payable has ranged from 8.57 to 18.37. According to the industry distribution chart, ACME Laboratories ranks #909 out of 919 companies in the Drug Manufacturers industry, placing it in the top 98.9%.
Is ACME Laboratories' Days Payable too high?
ACME Laboratories' current Days Payable of 7.59 is 29% below median its 10-year median of 10.71. Over the past 10 years, this metric has ranged from a low of 8.57 to a high of 18.37. The Drug Manufacturers industry median Days Payable is 90.69. ACME Laboratories' value of 7.59 is 91.6% below this industry median. Based on the distribution chart, ACME Laboratories ranks #909 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #909 out of 919 companies for Days Payable. This places ACME Laboratories in the lower half of its industry. The industry median Days Payable is 90.69. ACME Laboratories' value of 7.59 is 91.6% below this benchmark. Historically, ACME Laboratories' own Days Payable has ranged from 8.57 to 18.37 over the past decade. While the company's 10-year median is 10.71 vs. the industry median of 90.69, ACME Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Days Payable of 7.59 is 91.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Days Payable is 7.59, which is 29% below median its own 10-year median of 10.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.14, compared to a current price of BDT82.60 — trading 34% below its estimated fair value. The current Days Payable is 7.59, which is 29% below median its 10-year median of 10.71 and 91.6% below the Drug Manufacturers industry median of 90.69. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Days Payable is 7.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT82.60 is trading 34% below its estimated GF Value™ of BDT125.14.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Days Payable: 7.59 (29% below median its 10-year median of 10.71)
GF Value™: BDT125.14 vs. price of BDT82.60 (34% below fair value)
Industry Position: 91.6% below the Drug Manufacturers median (#909 of 919)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
